CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 86 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,674 | +117.5% | 3,755 | +31.8% | 0.01% | +200.0% |
| Q2 2023 | $51,339 | +12.2% | 2,849 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $45,755 | -21.6% | 2,849 | -10.7% | 0.00% | -33.3% |
| Q4 2022 | $58,395 | -6.8% | 3,191 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $62,671 | +5.3% | 3,191 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $59,512 | -1.8% | 3,191 | +15.5% | 0.00% | +50.0% |
| Q1 2022 | $60,626 | -82.0% | 2,762 | -76.6% | 0.00% | -60.0% |
| Q4 2021 | $335,948 | +65.2% | 11,825 | +22.4% | 0.01% | +66.7% |
| Q3 2021 | $203,343 | +11.7% | 9,660 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,091 | +55.0% | 9,660 | +25.7% | 0.00% | +50.0% |
| Q1 2021 | $117,442 | -5.3% | 7,686 | -12.6% | 0.00% | 0.0% |
| Q4 2020 | $124,055 | -10.0% | 8,792 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $137,771 | -10.6% | 8,792 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $154,036 | +151.1% | 8,792 | +110.7% | 0.00% | +200.0% |
| Q1 2020 | $61,343 | -41.4% | 4,173 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $104,701 | +352.8% | 4,173 | +351.1% | 0.00% | – |
| Q2 2019 | $23,125 | – | 925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |